Achievement of Different Treatment Targets with Izokibep
Demonstrates Efficacy Benefits in Patients with Active
Psoriatic Arthritis: Results from a 16-Week Randomized,
Placebo-Controlled Phase 2 Clinical Trial

a 2022

Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial

BEHRENS, Frank, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL et. al.

Základní údaje

Originální název

Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial

Autoři

BEHRENS, Frank, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL, Nicolai BRUN, Brian WIENS, Jan BRANDT-JUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ (203 Česká republika, domácí), Anna ROWINSKA-OSUCH, Martin Nadia ABDEL-KADER a Kurt DE VLAM

Vydání

2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 13.300

Kód RIV

RIV/00216224:14160/22:00128080

Organizační jednotka

Farmaceutická fakulta

ISSN

UT WoS

000877386504096

Klíčová slova anglicky

Izokibep; efficacy; psoriatic arthriris; clinical trial

Štítky

rivok, ÚFT

Příznaky

Mezinárodní význam

Změněno: 19. 1. 2023 09:25, JUDr. Sabina Krejčiříková

Anotace

V originále

Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations (arthritis, spondylitis, enthesitis, dactylitis, skin, nails). IL-17 inhibitors have shown efficacy across all disease domains. Izokibep, a first-in-class fusion protein, is a unique IL-17A inhibitor with very high potency (Kd =0.3 pM), small molecular size (18.6 kD versus mAbs ~ 150 kD), and attachment to albumin. Treat to target is an important strategy to optimize disease control (reducing inflammation, limiting damage) as well as optimizing quality of life in PsA. Many composite measures of disease control have been proposed for clinical decision-making, including ACR scores, DAS28-CRP, DAPSA scores, and MDA. Here, we report the efficacy results of izokibep 40 mg Q2W and 80 mg Q2W versus placebo across a range of disease outcome measures as well as relevant safety data over 16 weeks compared to placebo.

Citovat

BEHRENS, Frank, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL, Nicolai BRUN, Brian WIENS, Jan BRANDT-JUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ, Anna ROWINSKA-OSUCH, Martin Nadia ABDEL-KADER a Kurt DE VLAM. Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial. 2022. ISSN 2326-5191.

@proceedings{2247552,
   author = {Behrens, Frank and Taylor, Peter and Mease, Philip J. and Peloso, Paul and Wetzel, Dieter and Brun, Nicolai and Wiens, Brian and BrandtandJuergens, Jan and Drescher, Edit and Dokoupilová, Eva and RowinskaandOsuch, Anna and AbdelandKader, Martin Nadia and de Vlam, Kurt},
   keywords = {Izokibep; efficacy; psoriatic arthriris; clinical trial},
   language = {eng},
   title = {Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial},
   url = {https://acrabstracts.org/abstract/achievement-of-different-treatment-targets-with-izokibep-demonstrates-efficacy-benefits-in-patients-with-active-psoriatic-arthritis-results-from-a-16-week-randomized-placebo-controlled-phase-2-clini/},
   year = {2022}
}

TY  - CONF
ID  - 2247552
AU  - Behrens, Frank - Taylor, Peter - Mease, Philip J. - Peloso, Paul - Wetzel, Dieter - Brun, Nicolai - Wiens, Brian - Brandt-Juergens, Jan - Drescher, Edit - Dokoupilová, Eva - Rowinska-Osuch, Anna - Abdel-Kader, Martin Nadia - de Vlam, Kurt
PY  - 2022
TI  - Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial
KW  - Izokibep
KW  - efficacy
KW  - psoriatic arthriris
KW  - clinical trial
UR  - https://acrabstracts.org/abstract/achievement-of-different-treatment-targets-with-izokibep-demonstrates-efficacy-benefits-in-patients-with-active-psoriatic-arthritis-results-from-a-16-week-randomized-placebo-controlled-phase-2-clini/
N2  - Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations (arthritis, spondylitis, enthesitis, dactylitis, skin, nails). IL-17 inhibitors have shown efficacy across all disease domains. Izokibep, a first-in-class fusion protein, is a unique IL-17A inhibitor with very high potency (Kd =0.3 pM), small molecular size (18.6 kD versus mAbs ~ 150 kD), and attachment to albumin. Treat to target is an important strategy to optimize disease control (reducing inflammation, limiting damage) as well as optimizing quality of life in PsA. Many composite measures of disease control have been proposed for clinical decision-making, including ACR scores, DAS28-CRP, DAPSA scores, and MDA. Here, we report the efficacy results of izokibep 40 mg Q2W and 80 mg Q2W versus placebo across a range of disease outcome measures as well as relevant safety data over 16 weeks compared to placebo.
ER  -

BEHRENS, Frank, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL, Nicolai BRUN, Brian WIENS, Jan BRANDT-JUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ, Anna ROWINSKA-OSUCH, Martin Nadia ABDEL-KADER a Kurt DE VLAM. \textit{Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial}. 2022. ISSN~2326-5191.

Podrobný výpis o publikaci